{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:48:19Z","timestamp":1784566099388,"version":"3.55.0"},"reference-count":26,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Eravaycline is a novel fully synthetic fluorocycline that is currently approved for complicated intra-abdominal infections. However, it is sometimes also used off-label in tertiary care centers for other infection sites as an antibiotic of last resort due to its broad spectrum of activity and efficacy against Enterobacterales, including multidrug-resistant pathogens like extended spectrum \u03b2-lactamase (ESBL) producers or carbapenem-resistant Enterobacterales, as well as all Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin- and linezolid-resistant Enterococcus faecium (VRE). Methods: We retrospectively included a total of 78 patients from Austria and Udine who received eravacycline between April 2023 and August 2024 to evaluate the real-world efficacy of eravacycline in various infection sites and pathogens using descriptive statistics. Results: Eravacycline was most commonly used in intra-abdominal infections (44.9%), followed by pneumonia (12.8%) and infections of unknown origin (7.7%). Escherichia coli, including ESBL producers, was the most common pathogen (24.4%), followed by Enterococcus spp. (12.8%) and Klebsiella pneumoniae (12.8%). Clinical cure was achieved in 65% of patients, whereas microbiological cure was documented in 46%; source control was attained in 48.7%, and 16.7% died within 30 days. A total of 48% of patients required intensive care. Conclusions: Eravacycline represents a possible therapeutic option for a wide range of pathogens, but its use must be evaluated in the context of infection site and severity.<\/jats:p>","DOI":"10.3390\/antibiotics15040421","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:10:44Z","timestamp":1776787844000},"page":"421","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Experience on the Use of Eravacycline at Doses of 1 mg\/kg Bodyweight and Fixed Dose Strategy in Two European Tertiary Centers"],"prefix":"10.3390","volume":"15","author":[{"given":"Karin","family":"Oberreiter","sequence":"first","affiliation":[{"name":"Clinical Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam M.","family":"Moser","sequence":"additional","affiliation":[{"name":"Clinical Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Department of Neurosurgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Schneider","sequence":"additional","affiliation":[{"name":"Clinical Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Burgmann","sequence":"additional","affiliation":[{"name":"Clinical Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-7581","authenticated-orcid":false,"given":"Chiara","family":"Moreal","sequence":"additional","affiliation":[{"name":"Department of Medicine (DMED), University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2475-8732","authenticated-orcid":false,"given":"Simone","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Department of Specialistic Medicine, University Hospital of Central Friuli, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8433-0394","authenticated-orcid":false,"given":"Jacopo","family":"Angelini","sequence":"additional","affiliation":[{"name":"Department of Medicine (DMED), University of Udine, 33100 Udine, Italy"},{"name":"Clinical Pharmacology and Toxicology Institute, University Hospital Friuli Centrale ASUFC, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[{"name":"Department of Medicine (DMED), University of Udine, 33100 Udine, Italy"},{"name":"Infectious Diseases Clinic, Department of Specialistic Medicine, University Hospital of Central Friuli, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4350-7173","authenticated-orcid":false,"given":"Matthias G.","family":"Vossen","sequence":"additional","affiliation":[{"name":"Clinical Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/phar.2366","article-title":"Evaluation of Eravacycline: A Novel Fluorocycline","volume":"40","author":"Alosaimy","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1021\/jm201465w","article-title":"Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A potent, broad spectrum antibacterial agent","volume":"55","author":"Xiao","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rusu, A., and Buta, E.L. (2021). The Development of Third-Generation Tetracycline Antibiotics and New Perspectives. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122085"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"ref_5","unstructured":"European Medicines Agency (EMA) (2024, September 02). Tygacil|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tygacil."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"16581","DOI":"10.1038\/s41598-025-98206-6","article-title":"Emergence of transferable tigecycline and eravacycline resistance gene tet(X4) in Escherichia coli isolates from Iran","volume":"15","author":"Haeili","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_7","unstructured":"European Medicines Agency (EMA) (2024, September 02). Xerava, INN-Eravacycline. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xerava."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2217\/fmb-2019-0135","article-title":"Eravacycline: A new treatment option for complicated intra-abdominal infections in the age of multidrug resistance","volume":"14","author":"Solomkin","year":"2019","journal-title":"Future Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e0235123","DOI":"10.1128\/spectrum.02351-23","article-title":"Eravacycline, the first four years: Health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022","volume":"12","author":"Alosaimy","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40262-019-00767-z","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline","volume":"58","author":"McCarthy","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jgar.2025.09.011","article-title":"The efficacy and safety of eravacycline in the treatment of patients with pneumonia in respiratory departments: A real-world multicenter retrospective study","volume":"45","author":"Luo","year":"2025","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e0106524","DOI":"10.1128\/aac.01065-24","article-title":"Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK\/PD","volume":"69","author":"Ji","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1177\/10600280221085551","article-title":"Efficacy of Eravacycline Versus Best Previously Available Therapy for Adults With Pneumonia Due to Difficult-to-Treat Resistant (DTR) Acinetobacter baumannii","volume":"56","author":"Scott","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/QCO.0000000000000438","article-title":"New antibiotics for ventilator-associated pneumonia","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_18","unstructured":"FDA U.S. Food and Drug Administration (2025, October 24). Xerava Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211109lbl.pdf."},{"key":"ref_19","unstructured":"(2025, November 14). Dosing & Administration|XERAVA\u00ae (Eravacycline). Available online: https:\/\/www.xerava.com\/dosing."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10096-019-03590-3","article-title":"Eravacycline, a newly approved fluorocycline","volume":"38","author":"Lee","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40121-020-00351-0","article-title":"A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline","volume":"9","author":"Petrak","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"ofaa071","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early Experience With Eravacycline for Complicated Infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"028","DOI":"10.1055\/s-0041-1740973","article-title":"Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection","volume":"43","author":"Carlson","year":"2022","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgar.2024.03.014","article-title":"Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: A clinical microbiological study","volume":"37","author":"Tsai","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"Vogelzang","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s13054-024-05150-4","article-title":"The relation between inflammatory biomarkers and drug pharmacokinetics in the critically ill patients: A scoping review","volume":"28","author":"Li","year":"2024","journal-title":"Crit. Care"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/4\/421\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:25:28Z","timestamp":1777379128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/4\/421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["antibiotics15040421"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15040421","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}